Telix Pharma Shares Jump 12% After US FDA Approves Pixclara

Telix Pharmaceuticals shares surged after the U.S. Food and Drug Administration approved Pixclara, a radioactive diagnostic imaging agent for glioma brain cancer, marking the first regulatory clearance of its kind in the United States, according to an Investing.com report.

Following the regulatory announcement, Telix shares jumped as much as 12% to reach A$17.65 in Sydney trading before paring gains to trade up 2.6% for the session. The sharp move extends a multi-month run for the radiopharmaceutical developer, with the stock posting gains of nearly 43% since the start of 2026.

What Is Pixclara?

Pixclara is designed specifically for the management of glioma, a primary tumor that begins in the brain or spine. As a radioactive diagnostic drug, the agent helps clinicians visualize and evaluate cancerous lesions using imaging techniques, providing a specialized tool for neuro-oncology diagnostics where prior approved options were limited.

Market Position and 2026 Performance

The FDA approval reinforces Telix's commercial footprint in the radiopharmaceuticals sector. The company's pipeline developments and diagnostic approvals have driven sustained investor interest, reflected in the stock's 43% year-to-date appreciation.

Market participants continue to monitor how upcoming commercial distribution channels for Pixclara will impact revenue generation as the product enters the U.S. healthcare market.